Avecho Biotechnology Limited

AVE

AU0000047441

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:23 29/05/2024 am IST			5-day change	1st Jan Change
0.003 ^AUD	-25.00%		0.00%	-14.29%

16/05	Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	MT
25/03	Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	MT

Phosphagenics Limited Appoints David Segal as Non-Executive Director

May 19, 2016 at 08:00 am IST

Phosphagenics Limited announced that following its annual general meeting the Board announced the appointment of Mr. David Segal as a Non-Executive Director.

Latest news about Avecho Biotechnology Limited

Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	16/05	MT
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	26/03	MT
Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug	14/03	MT
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial	07/03	MT
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
Avecho Biotechnology Achieves Two-Year Stability Milestone for CBD Capsule	22/23/22	MT
US Patent Office Allows Avecho Biotechnology's Patent on 'Optimized' Manufacturing Method for Tocopheryl Phosphate Mixture	29/23/29	MT
Avecho Biotechnology Signs Licensing Deal with Arthur Group for Development of Cancer Drugs	22/23/22	MT
Avecho Biotechnology Begins Manufacturing for Oral Cannabidiol Capsules	17/23/17	MT
Avecho Biotechnology Raises AU$2 Million Via Entitlement Offer; Shares Slip 20%	09/23/09	MT
Avecho Biotechnology Conducts Entitlement Offer to Raise $11 Million to Fund Pivotal Phase Iii Clinical Trial	03/23/03	CI
Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt	15/23/15	CI
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Avecho Biotechnology Expands Research Partnership for Cannabidiol Medication	22/23/22	MT
Avecho Biotechnology Limited Announces Ongoing Collaboration with Lambert Initiative	22/23/22	CI
Athenex Pharmaceutical Division Submits Avecho's Vitamin K Injection to US FDA	12/23/12	MT
Athenex Submits Avecho's Phytonadione to FDA Pre-IND	12/23/12	CI
Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial	22/22/22	MT
Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia	22/22/22	CI
Avecho Biotechnology Signs Development Deal for TPM-enhanced Ibuprofen Gel for US market; Shares Up 10%	20/22/20	MT
Avecho Biotechnology Limited Signs Development Agreement with Perrigo Company plc	20/22/20	CI
Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study	19/22/19	MT
Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk	19/22/19	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI

Chart Avecho Biotechnology Limited

Duration

Period

More charts

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVECHO BIOTECHNOLOGY LIMITED	-14.29%	8.44M
MODERNA, INC.	+48.67%	58.71B
IQVIA HOLDINGS INC.	-2.76%	41.31B
LONZA GROUP AG	+36.42%	39.2B
CELLTRION, INC.	-11.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+9.25%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-23.10%	18.98B
BIO-TECHNE CORPORATION	+1.88%	12.51B
MEDPACE HOLDINGS, INC.	+26.43%	12.08B
UNITED THERAPEUTICS CORPORATION	+21.74%	11.94B